Dr. Dessein, et al reply

PATRICK H. DESSEIN, BERENICE F. CHRISTIAN and AHMED SOLOMON

J Rheumatol 2010;37;201-202
http://www.jrheum.org/content/37/1/201

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
We thank Drs. Ravindran and Hughes for their encouraging comments on our study in which we identified determinants of dyslipidemia in public and private healthcare patients with established rheumatoid arthritis (RA)\(^1\). Ravindran and Hughes further estimated the proportion of patients with RA that should receive preventive treatment for cardiovascular disease (CVD) according to the Joint British Societies (JBS) guidelines\(^2\). As recommended\(^3\), they further adjusted for the presence of RA inflammation by doubling the multifactorial 10-year risk score as estimated using the modified JBS2 CVD risk calculator\(^2\). Of the 65 patients investigated, 57\% had JBS-defined cardiovascular comorbidities indicative of a necessity for CVD prevention\(^7\). Upon multifactorial 10-year risk evaluation\(^2\) in the remaining patients, this proportion of patients increased to 63\% and upon further adjustment for the presence of RA inflammation\(^3\), it increased to 72\%. Thus, about 3 in 4 of their patients with RA needed cardiovascular risk management.

The bulk of the cardiovascular disease burden is now found in populations living in low- and middle-income countries\(^4\). Socioeconomic deprivation enhances RA severity\(^5\)\(^6\) but whether it alters the need for CVD prevention in RA is unknown. Together with the findings of Ravindran and Hughes this prompted us to estimate the potential effects of public healthcare attendance as a marker of socioeconomic disadvantage on the need for lifestyle intervention and/or the use of cardiovascular drugs according to the JBS guidelines, and with adjustment for the presence of RA inflammation\(^2\)\(^3\).

The baseline characteristics in our patients were reported previously\(^1\). We studied 424 public and 202 private healthcare patients. Their mean (SD) age and disease duration were 55.9 (11.6) and 9.2 (2.4) years, respectively, and 84.5\% were women. Table 1 shows the JBS-defined cardiovascular comorbidities\(^2\) that were present. Public healthcare attendance was associated with a heightened prevalence of JBS-defined hypertension (OR 2.01, 95\% CI 1.43–2.84) and JBS-defined dyslipidemia (OR 3.40, 95\% CI 1.42–8.18). Sixty-two percent of public and 42\% of private healthcare patients had 1 or more JBS-defined cardiovascular comorbidities (OR 2.27, 95\% CI 1.61–3.20). In the remaining patients, these numbers increased to 63\% and upon further adjustment for RA inflammation\(^3\), these numbers increased to 18 in public and 32 in private healthcare attendance as a marker of socioeconomic disadvantage on the need for lifestyle intervention and/or the use of cardiovascular drugs according to the JBS guidelines, and with adjustment for the multifactorial 10-year risk score of RA inflammation\(^2\)\(^3\). The mean (SD) 10-year risk was 5.5 (5.1) in public care and 5.4 (5.1) in private care patients (p = 0.7 by Student t test). Table 2 shows that this procedure identified another 3 patients who qualified for CVD prevention (10-year risk > 20\%) in each healthcare sector. Upon further adjustment for RA inflammation\(^3\), these numbers increased to 18 in public and 19 in private healthcare attendance. When we added these patients to those with 1 or more JBS-defined cardiovascular comorbidities, 66.8\% in public and 52.2\% in private healthcare needed CVD risk management (OR 1.87, 95\% CI 1.33–2.64). Our proportions of patients who required CVD risk management were somewhat lower than those reported by Ravindran and Hughes, presumably at least in part because our patients were on average 7 years younger. The JBS guidelines aim at preventing fatal and nonfatal coronary heart disease and stroke. They are based on information mainly obtained in Caucasians\(^2\). Forty-six percent of our patients were black and 7\% were of mixed ancestry. It is, however, unlikely that the application of the JBS guidelines in our healthcare setting results in overestimating the need for CVD risk management. Although reported information on CVD in black Africans and in those of mixed ancestry is limited, ischemic heart disease is reportedly less prevalent in these populations, but they experience a higher prevalence of stroke relative to their European counterparts\(^7\). Further, the INTERHEART investigators recently documented that the association between cardiovascular risk factors and ischemic heart disease is consistent worldwide including in Africa\(^4\)\(^7\). Moreover, the association between hypertension and acute myocardial infarction is even stronger in black Africans than in other populations\(^7\).

Our findings confirm that over 50\% of patients with RA need CVD prevention. We further show for the first time that socioeconomic disadvantage in patients with RA markedly augments the requirement for systematic CV risk management.

PATRICK H. DESSEIN, MD, FCP(SA), FRCP(London), PhD, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Milpark Hospital, Johannesburg, South Africa, and Department of Rheumatology.
REFERENCES


J Rheumatol 2010;37:1; doi:10.3899/jrheum.090910